AstraZeneca PLC (AZN)vsPDD Holdings Inc. (PDD)
AZN
AstraZeneca PLC
$185.78
+0.93%
HEALTHCARE · Cap: $284.63B
PDD
PDD Holdings Inc.
$102.61
+4.61%
CONSUMER CYCLICAL · Cap: $139.25B
Smart Verdict
WallStSmart Research — data-driven comparison
PDD Holdings Inc. generates 613% more annual revenue ($418.54B vs $58.74B). PDD leads profitability with a 24.4% profit margin vs 17.4%. PDD appears more attractively valued with a PEG of 1.03. PDD earns a higher WallStSmart Score of 77/100 (B+).
AZN
Strong Buy66
out of 100
Grade: B-
PDD
Strong Buy77
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+32.8%
Fair Value
$306.07
Current Price
$185.78
$120.29 discount
Margin of Safety
+67.8%
Fair Value
$332.33
Current Price
$102.61
$229.72 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Attractively priced relative to earnings
Every $100 of equity generates 31 in profit
Conservative balance sheet, low leverage
Generating 45.7B in free cash flow
Safe zone — low bankruptcy risk
Large-cap with strong market position
Areas to Watch
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
No major concerns identified
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : PDD
The strongest argument for PDD centers on P/E Ratio, Return on Equity, Debt/Equity. Profitability is solid with margins at 24.4% and operating margin at 23.1%. PEG of 1.03 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Revenue Growth, Altman Z-Score.
Bear Case : PDD
No major red flags identified for PDD, but monitor valuation.
Key Dynamics to Monitor
AZN profiles as a value stock while PDD is a mature play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.23 — expect wider price swings.
PDD is growing revenue faster at 9.0% — sustainability is the question.
PDD generates stronger free cash flow (45.7B), providing more financial flexibility.
Bottom Line
PDD scores higher overall (77/100 vs 66/100), backed by strong 24.4% margins. AZN offers better value entry with a 32.8% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
PDD Holdings Inc.
CONSUMER CYCLICAL · INTERNET RETAIL · China
Pinduoduo Inc., operates an electronic commerce platform in the People's Republic of China. The company is headquartered in Shanghai, the People's Republic of China.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?